Should tyrosine kinase inhibitors be considered for advanced non-small-cell lung cancer patients with wild type EGFR? Two systematic reviews and meta-analyses of randomized trials

Clinical Lung Cancer

Volumn 16, Issue 3, 2015, Pages 173-182.e4

  Vale, Claire L ^a   Burdett, Sarah ^a   Fisher, David J ^a   Navani, Neal ^b   Parmar, Mahesh K B ^a   Copas, Andrew J ^a   Tierney, Jayne F ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Chemotherapy; Meta analysis; NSCLC; RCT; TKI

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; GENE MUTATION; HUMAN; MAINTENANCE CHEMOTHERAPY; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; WILD TYPE; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84928695218     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2014.11.007     Document Type: Review

References (46)

1. M. Fukuoka, Y.L. Wu, and S. Thongprasert Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 29 2011 2866 2874
2. R. Rosell, E. Carcereny, and R. Gervais Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
3. M. Makoto, I. Akira, and K. Kunihiko Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
4. Z. Caicun, W. Yi-Long, and C. Gongyan Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
5. T. Mitsudomi, S. Morita, and Y. Yatabe Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
6. C.G. Azzoli, S. Baker, and S. Temin American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer J Clin Oncol 27 2009 6251 6266
7. S. Peters, A.A. Adjei, and C. Gridelli Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 suppl 7 2012 vii56 vii64
8. M.C. Garassino, O. Martelli, and M. Broggini Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial Lancet Oncol 14 2013 981 988
9. Q. Zhou, Y. Cheng, and M.F. Zhao Final results of CTONG 0806: a phase II trial comparing pemetrexed with gefitinib as second-line treatment of advanced non-squamous NSCLC patients with wild-type EGFR J Thorac Oncol 8 Suppl 2 2013 S194 (abstract O15.07)
10. F. Petrelli, K. Borgonovo, M. Cabiddu, and S. Barni Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials Clin Lung Cancer 13 2012 107 114
11. H. Gao, X. Ding, and D. Wei Efficacy of erlotinib in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized trials Anticancer Drugs 22 2011 842 852
12. C.K. Lee, C. Brown, and R.J. Gralla Impact of EGFR inhibitor in non-small-cell lung cancer on progression-free and overall survival: a meta-analysis J Natl Cancer Inst 105 2013 595 605
13. J.K. Lee, S. Hahn, and D.W. Kim Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis JAMA 311 2014 1430 1437
14. D.J. Fisher, A.J. Copas, J.F. Tierney, and M.K. Parmar A critical review of methods for the assessment of patient-level interactions in individual patient data (IPD) meta-analysis of randomised trials, and guidance for practitioners J Clin Epidemiol 64 2011 949 967
15. G. Ellison, G. Zhu, and A. Moulis EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples J Clin Pathol 66 2013 79 89
16. J.P. Higgins, and S.J. Green Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration 2011 Available from www.cochrane-handbook.org
17. J.P. Higgins, D.G. Altman, and P.C. Gotzsche The Cochrane Collaboration's tool for assessing risk of bias in randomised trials BMJ 343 2011 d5928
18. M.K. Parmar, V. Torri, and L.A. Stewart Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 1998 2815 2834
19. P.R. Williamson, C. Tudur Smith, J.L. Hutton, and A.G. Marson Aggregate data meta-analysis with time-to-event outcomes Stat Med 21 2002 3337 3351
20. J.F. Tierney, L.A. Stewart, D. Ghersi, S. Burdett, and M.R. Sydes Practical methods for incorporating summary time-to-event data into meta-analysis Trials 8 2007 16
21. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
22. The International Collaborative Ovarian Neoplasm (ICON) Group Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphomide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial Lancet 360 2002 505 515
23. A.R. Bhatnagar, D.P. Singh, R. Sharma, and P. Kumbhaj Docetaxel versus gefitinib in patients with locally advanced or metastatic NSCLC pre-treated with platinum-based chemotherapy J Thorac Oncol 7 Suppl 3 2012 S159 (abstract 102-P12)
24. D.M. Dilts, A.A. Adjei, and S.J. Mandrekar Impact of trial development time on accruals at CCOPs: the case of the MARVEL trial J Clin Oncol 28 15 suppl (May 20 Supplement) 2010 e16505
25. J.C. Soria, F. Barlesi, and B. Besse Results of the prospective, randomized, and customized NSCLC adjuvant phase II trial (IFCT-0801, TASTE trial) from the French Collaborative Intergroup (abstract 7505) J Clin Oncol 31 2013 No 15 suppl (May 20 Supplement)
26. T. Cufer, E. Vrdoljak, and R. Gaafar Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer Anticancer Drugs 17 2006 401 409
27. R. Maruyama, Y. Nishiwaki, and T. Tamura Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer J Clin Oncol 26 2008 4244 4252
28. R.S. Herbst, V.J. O'Neill, and L. Fehrenbacher Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer J Clin Oncol 25 2007 4743 4750
29. J.Y. Douillard, F.A. Shepherd, and V. Hirsh Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial J Clin Oncol 2009 2010 744 752
30. D.H. Lee, K. Park, and J.H. Kim Randomized phase III trial of gefitinib versus docetaxel in non-small-cell lung cancer patients who have previously received platinum-based chemotherapy Clin Cancer Res 16 2010 1307 1314
31. T. Ciuleanu, L. Stelmakh, and S. Cicenas Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study Lancet Oncol 13 2012 300 308
32. A. Karampeazis, A. Voutsina, and J. Souglakos Pemetrexed versus erlotinib in pretreated patients with advanced non-small-cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study Cancer 119 2013 2754 2764
33. M.J. Ahn, J.M. Sun, and S.W. Kim Randomized phase III trial of gefitinib or pemetrexed as second line treatment in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01) J Thorac Oncol 6 Suppl 2 2011 s317 (abstract no O10.04)
34. V. Gregorc, S. Novello, and C. Lazzari Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherpay (PROSE): a biomarker-statified, randomised phase 3 trial Lancet Oncol 15 2014 713 721
35. T. Kawaguchi, M. Ando, and K. Asami Randomised phase III trial of erlotinib versus docetaxel as second or third-line therapy in patients with advanced non-small-cell lung cancer: docetaxel and erlotinib lung cancer trial (DELTA) J Clin Oncol 32 2014 1902 1908
36. H. Li, X. Wang, and F. Hua Second-line treatment with gefitinib or docetaxel for advanced non-small-cell lung cancer [in Chinese] Chin J Clin Oncol 37 2010 16 18
37. N. Li, W. Ou, and H. Yang A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma Cancer 120 2014 1379 1386
38. F. Cappuzzo, T. Ciuleanu, and L. Stelmakh Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
39. M. Perol, C. Chouaid, and D. Perol Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 30 2012 3516 3524
40. R.M. Gaafar, V.F. Surmont, and G.V. Scagliotti A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03) Eur J Cancer 47 2011 2331 2340
41. L. Zhang, S. Ma, and X. Song Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double blind randomised phase 3 trial Lancet Oncol 13 2012 466 475
42. K. Kelly, K. Chansky, and L.E. Gaspar Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023 J Clin Oncol 26 2008 2450 2456
43. F. Kabbinavar, L. Fehrenbacher, and J. Hainsworth Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with our without erlotinib as maintenance therapy for treatment of advanced non-small-cell lung cancer (ATLAS) J Thorac Oncol 9 2014 1411 1417
44. C.L. Vale, J.F. Tierney, and S. Burdett Can trial quality be reliably assessed from published reports of cancer trials: evaluation of risk of bias assessments in systematic reviews BMJ 346 2013 f1798
45. J.A. Berlin, J. Santanna, and C.H. Schmid Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head Stat Med 21 2002 371 387
46. S.J. Pocock, and R. Simon Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial Biometrics 31 1975 103 115